{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:48:17Z","timestamp":1775008097932,"version":"3.50.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972931"],"award-info":[{"award-number":["81972931"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.semarthrit.2020.12.007","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T16:33:56Z","timestamp":1608827636000},"page":"198-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Understanding of cytokines and targeted therapy in macrophage activation syndrome"],"prefix":"10.1016","volume":"51","author":[{"given":"Shunli","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingxian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanyin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.12.007_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic Lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis","volume":"63","author":"Janka","year":"2012","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0003","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0004","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OARRR.S151013","article-title":"Macrophage activation syndrome: early diagnosis is key","volume":"10","author":"Lerkvaleekul","year":"2018","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0006","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0007","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s10067-020-04949-0","article-title":"Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0008","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40272-019-00367-1","article-title":"Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management","volume":"22","author":"Henderson","year":"2020","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0010","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jpeds.2004.12.016","article-title":"Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"146","author":"Ravelli","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"Ravelli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0012","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0013","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2019-215211","article-title":"Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"78","author":"Minoia","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0014","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3899\/jrheum.170955","article-title":"Macrophage activation syndrome in patients affected by adult-onset still disease: analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort","volume":"45","author":"Ruscitti","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.autrev.2017.05.010","article-title":"Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 103 episodes in 89 adult patients","volume":"16","author":"Gavand","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140289","article-title":"Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis","volume":"5","author":"Wilson","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.05.007","article-title":"Favorable Anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis","volume":"28","author":"Dimopoulos","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0018","doi-asserted-by":"crossref","first-page":"e27929","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0019","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0020","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2015-07-659813","article-title":"ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice","volume":"127","author":"Rood","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0021","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1182\/blood-2011-01-329607","article-title":"Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice","volume":"117","author":"Krebs","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0022","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1073\/pnas.1820704116","article-title":"Specific sequences of infectious challenge lead to secondary hemophagocytic lymphohistiocytosis-like disease in mice","volume":"116","author":"Wang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0023","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0024","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood-2017-11-814244","article-title":"Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis","volume":"132","author":"Chinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3899\/jrheum.100655","article-title":"Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis","volume":"38","author":"Yanagimachi","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0026","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013394","article-title":"Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still's disease","volume":"97","author":"Yashiro","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0027","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2001-11-0061","article-title":"Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model","volume":"101","author":"Jordan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0028","first-page":"363","article-title":"Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes","author":"Akilesh","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0029","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/art.37958","article-title":"Interferon-gamma mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice","volume":"65","author":"Canna","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0031","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0032","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/art.40683","article-title":"Brief Report: interferon-gamma-mediated immunopathology potentiated by Toll-Like Receptor 9 Activation in a Murine Model of Macrophage Activation Syndrome","volume":"71","author":"Weaver","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0033","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","article-title":"Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome","volume":"141","author":"Prencipe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0034","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/emmm.200900009","article-title":"Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice","volume":"1","author":"Pachlopnik Schmid","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0035","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.4049\/jimmunol.1501035","article-title":"Mouse cytomegalovirus infection in BALB\/c mice resembles virus-associated secondary hemophagocytic lymphohistiocytosis and shows a pathogenesis distinct from primary hemophagocytic lymphohistiocytosis","volume":"196","author":"Brisse","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0036","doi-asserted-by":"crossref","unstructured":"Canna, S.W. Editorial: interferon-gamma: friend or foe in systemic juvenile idiopathic arthritis and adult-onset Still's Disease? Arthritis Rheumatol66, 1072\u20136, doi:10.1002\/art.38362 (2014).","DOI":"10.1002\/art.38362"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0037","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/art.41076","article-title":"Genetic deficiency of interferon-gamma reveals interferon-gamma-independent manifestations of murine hemophagocytic lymphohistiocytosis","volume":"72","author":"Burn","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0038","doi-asserted-by":"crossref","unstructured":"Staines-Boone, A.T. et\u00a0al. Multifocal recurrent osteomyelitis and hemophagocytic lymphohistiocytosis in a boy with partial dominant IFN-gammaR1 deficiency: case report and review of the literature. Front Pediatr5, 75, doi:10.3389\/fped.2017.00075 (2017).","DOI":"10.3389\/fped.2017.00075"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0039","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-08-300046","article-title":"Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis","volume":"117","author":"Sumegi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.10.068","article-title":"IFN-gamma and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis","volume":"143","author":"Humblet-Baron","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.10.033","article-title":"A novel kindred with inherited STAT2 deficiency and severe viral illness","volume":"139","author":"Moens","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0042","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1164\/rccm.201903-0659OC","article-title":"Synergistic signaling of TLR and IFNalpha\/beta facilitates escape of IL-18 expression from endotoxin tolerance","volume":"201","author":"Verweyen","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0043","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0044","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","volume":"128","author":"Maschalidi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0046","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","article-title":"Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice","volume":"131","author":"Girard-Guyonvarc'h","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0047","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","article-title":"Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome","volume":"106","author":"Mazodier","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0048","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still's disease: comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0049","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0050","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0051","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1067\/mpd.2003.110","article-title":"Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"142","author":"Grom","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0052","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0053","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/art.33496","article-title":"Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome","volume":"64","author":"Strippoli","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0054","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","article-title":"Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages","volume":"105","author":"Billiau","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0055","doi-asserted-by":"crossref","first-page":"e88181","DOI":"10.1172\/jci.insight.88181","article-title":"A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment","volume":"1","author":"Wunderlich","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0056","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/art.39295","article-title":"Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome","volume":"67","author":"Cifaldi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0057","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1002\/art.38472","article-title":"A56: macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab","volume":"66","author":"Ravelli","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0058","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.12.1314","article-title":"IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis","volume":"138","author":"Humblet-Baron","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0060","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cyto.2013.03.007","article-title":"Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis","volume":"62","author":"Ishikawa","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0061","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.3389\/fimmu.2018.02642","article-title":"Disruption of IL-33 signaling limits early CD8+ T cell effector function leading to exhaustion in murine hemophagocytic lymphohistiocytosis","volume":"9","author":"Rood","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0062","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2016-09-738096","article-title":"Pharmacological targeting of plasmin prevents lethality in a murine model of macrophage activation syndrome","volume":"130","author":"Shimazu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0063","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0609.2004.00318.x","article-title":"Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome","volume":"74","author":"Schaer","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0064","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cyto.2018.05.017","article-title":"Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis","volume":"110","author":"Sakumura","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108252","article-title":"Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"208","author":"Takakura","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0066","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","article-title":"Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome","volume":"119","author":"Mizuta","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0067","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2019-216030","article-title":"Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"79","author":"Lee","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0068","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/cei.13026","article-title":"Characteristic elevation of soluble TNF receptor II: i ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis","volume":"191","author":"Shimizu","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0069","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr2.11048","article-title":"Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"1","author":"Eloseily","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clim.2009.02.005","article-title":"Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin","volume":"132","author":"Coca","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0071","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jca.21570","article-title":"Role of plasma exchange, leukocytapheresis, and plasma diafiltration in management of refractory macrophage activation syndrome","volume":"33","author":"Kinjo","year":"2018","journal-title":"J Clin Apher"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0072","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.41103","article-title":"Benefit of Anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","volume":"72","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0073","doi-asserted-by":"crossref","first-page":"887","DOI":"10.21037\/atm-20-3127","article-title":"Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still's disease: case report and review of the literature","volume":"8","author":"Gabr","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab","volume":"60","author":"Marsh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0076","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/RHU.0b013e31824e8d9b","article-title":"Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus","volume":"18","author":"Keith","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0077","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0078","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0079","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0080","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/art.41285","article-title":"On the Alert for Cytokine Storm: immunopathology in COVID-19","volume":"72","author":"Henderson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","volume":"111","author":"Liu","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0082","doi-asserted-by":"crossref","DOI":"10.20452\/pamw.15685","article-title":"Cytokines as a predictor of COVID-19 severity: evidence from meta-analysis","author":"Szarpak","year":"2020","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0083","article-title":"Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study","author":"Bozzi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0084","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/annrheumdis-2020-217706","article-title":"Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series","volume":"79","author":"Aouba","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0085","doi-asserted-by":"crossref","first-page":"18277","DOI":"10.1038\/s41598-020-75260-w","article-title":"Title: cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients","volume":"10","author":"Lorenz","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0086","article-title":"Preliminary predictive criteria for COVID-19 cytokine storm","author":"Caricchio","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30343-X","article-title":"Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study","volume":"2","author":"Webb","year":"2020","journal-title":"The Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0088","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.autrev.2016.09.016","article-title":"Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers","volume":"16","author":"Ruscitti","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0089","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10875-017-0439-x","article-title":"A personalized diagnostic and treatment approach for macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in adults","volume":"37","author":"Kumar","year":"2017","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0090","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s10067-017-3830-3","article-title":"Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients","volume":"36","author":"Ruscitti","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0091","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","article-title":"Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature","volume":"37","author":"Sonmez","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0092","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/0885066617711386","article-title":"Interleukin 1 receptor antagonist Anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis","volume":"34","author":"Wohlfarth","year":"2019","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0093","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/acr2.11135","article-title":"Continuous intravenous Anakinra infusion to calm the cytokine storm in macrophage activation syndrome","volume":"2","author":"Monteagudo","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0094","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/SHK.0000000000001454","article-title":"Hemophagocytic lymphohistiocytosis in critically ill patients","volume":"53","author":"Knaak","year":"2020","journal-title":"Shock"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ejh.13433","article-title":"Soluble interleukin-2 receptor (sIL-2r) level is a limited test for the diagnosis of adult secondary hemophagocytic lymphohistiocytosis","volume":"105","author":"Naymagon","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0096","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0097","doi-asserted-by":"crossref","first-page":"e28581","DOI":"10.1002\/pbc.28581","article-title":"The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis","author":"Bami","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0098","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3899\/jrheum.161286","article-title":"Application of the 2016 EULAR\/ACR\/PRINTO classification criteria for macrophage activation syndrome in patients with adult-onset still disease","volume":"44","author":"Ahn","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0099","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12519-019-00256-0","article-title":"Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China","volume":"16","author":"Zou","year":"2020","journal-title":"World J Pediatr"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41390-020-0843-4","article-title":"Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy","author":"Irabu","year":"2020","journal-title":"Pediatr Res"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0101","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00277-018-3254-4","article-title":"Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents-a single centre experience of 20 years","volume":"97","author":"Strenger","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0102","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00277-017-3117-4","article-title":"Uterine intravascular lymphoma as a cause of fever of unknown origin","volume":"96","author":"Hadjadj","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0103","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hon.2314","article-title":"Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients","volume":"35","author":"Cattaneo","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0104","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/qjmed\/hcx183","article-title":"Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis","volume":"111","author":"Zhou","year":"2018","journal-title":"QJM"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0105","first-page":"1275","article-title":"Lymphoma associated hemophagocytic syndrome: a single-center retrospective study","volume":"16","author":"Chang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0106","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/qjmed\/hcy103","article-title":"An effective diagnostic index for lymphoma-associated hemophagocytic syndrome","volume":"111","author":"Xie","year":"2018","journal-title":"QJM"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0107","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1002\/cam4.1669","article-title":"Primary bone marrow lymphoma: a hematological emergency in adults with fever of unknown origin","volume":"7","author":"Wang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0108","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2018.047","article-title":"Hemophagocytic lymphohistiocytosis in adults: low incidence of primary neoplasm as a trigger in a case series from Turkey","volume":"10","author":"Arslan","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.mayocpiqo.2018.06.006","article-title":"Prognostic factors of death in 151 adults with hemophagocytic syndrome: etiopathogenically driven analysis","volume":"2","author":"Brito-Zeron","year":"2018","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0110","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/10245332.2018.1491093","article-title":"Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center","volume":"23","author":"Lai","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0111","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.transci.2018.10.001","article-title":"What's in a name? The heterogeneous clinical spectrum and prognostic factors in a cohort of adults with hemophagocytic lymphohistiocytosis","volume":"57","author":"Prokesch","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0112","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3324\/haematol.2018.198655","article-title":"Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy","volume":"104","author":"Yoon","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0113","doi-asserted-by":"crossref","first-page":"149","DOI":"10.14740\/jh592","article-title":"Hemophagocytic lymphohistiocytosis in adults: associated diagnoses and outcomes, a ten-year experience at a single institution","volume":"8","author":"Jumic","year":"2019","journal-title":"J Hematol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0114","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00277-020-04083-6","article-title":"A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study","volume":"99","author":"Yoon","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0115","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10875-020-00789-4","article-title":"Thinking beyond HLH: clinical features of patients with concurrent presentation of hemophagocytic lymphohistiocytosis and thrombotic microangiopathy","volume":"40","author":"Gloude","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0116","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","article-title":"Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis","volume":"2","author":"Juliana","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0117","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/cncr.31893","article-title":"A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis","volume":"125","author":"Chellapandian","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0118","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.seminhematol.2018.07.006","article-title":"Low dose ruxolitinib plus HLH-94 protocol: a potential choice for secondary HLH","volume":"57","author":"Wang","year":"2020","journal-title":"Semin Hematol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0119","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.16861","article-title":"L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis","volume":"191","author":"Zhao","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0120","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1007\/s00432-020-03301-y","article-title":"Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome","volume":"146","author":"Zhou","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0121","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12185-020-02936-4","article-title":"Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children","volume":"112","author":"Wei","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0122","article-title":"A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis","author":"Zhang","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semarthrit.2020.12.007_bib0123","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220303152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220303152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:05:35Z","timestamp":1758733535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220303152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0049017220303152"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.12.007","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding of cytokines and targeted therapy in macrophage activation syndrome","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}